Is sarcopenia effective on survival in patients with metastatic gastric cancer?

Table 1 Clinicopathologic characteristics of patients, n (%)

Patient characteristics	Sarcopenic	Non-sarcopenic	P value
Sex
Female	7 (24.1)	21 (23.6)	0.567
Male	22 (75.9)	68 (76.4)	N/A
Age in yr
< 65	12 (41.4)	48 (53.9)	0.288
≥ 65	17 (58.6)	41 (46.1)	N/A
PS score in points			0.197
0 or 1	19 (65.5)	69 (77.5)	N/A
2 or 3	10 (34.5)	20 (22.5)	N/A
Differentiation			0.823
Moderate or well	11 (44.0)	29 (41.4)	N/A
Poor	14 (56.0)	41 (58.6)	N/A
Smoking history			0.193
Yes	19 (65.5)	46 (51.7)	N/A
No	10 (34.5)	43 (48.3)	N/A
Number of metastatic sites			0.513
< 2	19 (65.5)	64 (71.9)	N/A
≥ 2	10 (34.5)	25 (28.1)	N/A
CEA level			0.295
< 5	10 (35.7)	40 (47.1)	N/A
≥ 5	18 (64.3)	45 (52.9)	N/A
BMI in kg/m2			0.427
Underweight, < 18.5	1 (3.4)	10 (11.2)	N/A
Normal, 18.5-24.9	18 (62.1)	47 (52.8)	N/A
Overweight, 25.0-29.9	7 (24.1)	27 (30.3)	N/A
Obese, > 30.0	3 (10.3)	5 (5.6)	N/A

BMI: Body mass index; CEA: Carcinoembryonic antigen; N/A: Not applicable; PS: Performance status.